Related Experiment Videos
The adrenergic system in lymphocytes from children with cystic fibrosis
A Schuster1, A Elsen, M Griese
1Zentrum für Kinderheilkunde der Universität Düsseldorf.
Insights
This study found no general defect in beta-adrenoceptors or adenylate cyclase in children with cystic fibrosis (CF). Lymphocyte studies confirmed normal receptor function, suggesting CF defects lie beyond these cellular mechanisms.
Area of Science:
- Cellular biology
- Pediatric medicine
- Pharmacology
Background:
- Previous research suggested potential beta-adrenoceptor defects in cystic fibrosis (CF) children, possibly explaining secretory imbalances.
- Investigating cellular mechanisms is crucial for understanding CF pathophysiology.
Purpose of the Study:
- To determine beta-adrenoceptor density and affinity on lymphocytes in children with CF.
- To assess cyclic AMP (cAMP) response to beta-adrenoceptor stimulation and direct adenylate cyclase activation in CF lymphocytes.
Main Methods:
- Radioligand binding assays using 125-iodo-cyano-pindolol (125-ICYP) to measure beta-adrenoceptor characteristics.
- Stimulation of lymphocytes with isoprenaline (IPN) and forskolin to evaluate cAMP production.
- Comparison between 20 children with CF and age-matched controls.
Main Results:
- Identical beta-adrenoceptor numbers and affinities were observed in lymphocytes of children with CF and controls.
- Cyclic AMP response was comparable between CF and control groups, irrespective of stimulation method (via beta-adrenoceptors or direct adenylate cyclase activation).
Conclusions:
- The study concludes that no general defect in beta-adrenoceptors or adenylate cyclase exists in cystic fibrosis.
- Findings suggest that abnormal adrenergic responses in CF patients may stem from defects located downstream of beta-adrenoceptors and cAMP signaling.
Abstract:
Several in vivo and in vitro studies have suggested that children suffering from cystic fibrosis (CF) might have a general defect of beta-adrenoceptors on the cell surface which might account for an unbalanced secretory process. In order to investigate if this view holds true, we determined the beta-adrenoceptor density and affinity on lymphocytes by means of radioligand studies using 125-iodo-cyano-pindolol (125-ICYP) in 20 children with CF. Cyclic AMP (cAMP) response was also investigated after specific beta-adrenoceptor stimulation with isoprenaline (IPN) and after direct stimulation of the adenylate cyclase with forskolin in lymphocytes. Children with CF and controls have identical numbers and affinities of beta-adrenoceptors on lymphocytes. The cyclic AMP response was identical in CF- and in age-matched control children regardless whether adenylate cyclase was stimulated directly or via beta-adrenoceptors. In conclusion, the data support the view that no general adrenoceptor or adenylate cyclase defect exists in CF. As several studies have found abnormal reactions to adrenergic stimuli in CF patients, we presume that there is a defect beyond the level of adrenergic receptors and cAMP which remains to be identified.